Source:Journal of Allergy and Clinical Immunology
Author(s): Kate L. Del Bel, Robert J. Ragotte, Aabida Saferali, Susan Lee, Suzanne M. Vercauteren, Sara A. Mostafavi, Richard A. Schreiber, Julie S. Prendiville, Min S. Phang, Jess Halperin, Nicholas Au, John M. Dean, Emily Jewels, Anne K. Junker, Paul C. Rogers, Michael Seear, Margaret L. McKinnon, Stuart E. Turvey
Teaser
Germline JAK1 gain-of-function mutations cause autosomal dominant immune dysregulation and hypereosinophilia with eosinophilic infiltration of the gastrointestinal tract, massive hepatosplenomegaly and severe atopic dermatitis that can be successfully treated with ruxolitinib, an oral JAK1/2 inhibitor.http://ift.tt/2jXwzOq
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου